These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 19300420)
1. Tyrosine kinase inhibitors in treatment of fibrous histiocytoma. Mauri D; Panou C; Valachis A; Kamposioras K; Tsali L Exp Oncol; 2009 Mar; 31(1):60-1. PubMed ID: 19300420 [TBL] [Abstract][Full Text] [Related]
2. Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Miyake H; Haraguchi T; Takenaka A; Fujisawa M Int J Clin Oncol; 2011 Apr; 16(2):153-5. PubMed ID: 20686910 [TBL] [Abstract][Full Text] [Related]
3. Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma. Aksu G; Ensaroglu F; Dolasik I; Temiz S; Halis H; Sener SY; Kaya A; Uygun K J BUON; 2010; 15(4):798-9. PubMed ID: 21229650 [No Abstract] [Full Text] [Related]
4. Metastatic collecting duct carcinoma of the kidney treated with sunitinib. Tazi EM; Essadi I; Tazi MF; Ahellal Y; M'rabti H; Errihani H World J Surg Oncol; 2011 Jul; 9():73. PubMed ID: 21752265 [TBL] [Abstract][Full Text] [Related]
5. [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report]. Yoshinaga A; Kamata S Hinyokika Kiyo; 2015 May; 61(5):201-5. PubMed ID: 26087822 [TBL] [Abstract][Full Text] [Related]
6. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U Oncology; 2009; 76(5):350-4. PubMed ID: 19321976 [TBL] [Abstract][Full Text] [Related]
7. [Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases]. Soto M; Campanario R; Saiz R; Juárez A Arch Esp Urol; 2016 Sep; 69(7):440-3. PubMed ID: 27617555 [TBL] [Abstract][Full Text] [Related]
8. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. Park CY Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356 [TBL] [Abstract][Full Text] [Related]
10. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]. Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Mahmood ST; Agresta S; Vigil CE; Zhao X; Han G; D'Amato G; Calitri CE; Dean M; Garrett C; Schell MJ; Antonia S; Chiappori A Int J Cancer; 2011 Oct; 129(8):1963-9. PubMed ID: 21154746 [TBL] [Abstract][Full Text] [Related]
12. Rare case of hemangiopericytoma responds to sunitinib. Mulamalla K; Truskinovsky AM; Dudek AZ Transl Res; 2008 Mar; 151(3):129-33. PubMed ID: 18279811 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Costero O; Picazo ML; Zamora P; Romero S; Martinez-Ara J; Selgas R Nephrol Dial Transplant; 2010 Mar; 25(3):1001-3. PubMed ID: 20019017 [TBL] [Abstract][Full Text] [Related]
14. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852 [TBL] [Abstract][Full Text] [Related]
16. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874 [TBL] [Abstract][Full Text] [Related]
17. Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy. Hoshi M; Takami M; Ieguchi M Radiat Med; 2008 Oct; 26(8):499-503. PubMed ID: 18975052 [TBL] [Abstract][Full Text] [Related]
18. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Wolter P; Beuselinck B; Pans S; Schöffski P Acta Oncol; 2009; 48(4):621-4. PubMed ID: 19107622 [No Abstract] [Full Text] [Related]
19. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936 [TBL] [Abstract][Full Text] [Related]